Pharmacy and Therapeutics Committee Updates

(From the July 2018 Issue of MedStat)

The following actions were taken at the 6/7/18 Pharmacy & Therapeutics Committee meeting:

  • Revisions to the Gadolinium-based and Iodinated Contrast Media Premeditation Guidelines were APPROVED
  • The H7B Pyxis Override List was APPROVED
  • Selexipag (Uptravi) tablets were ADDED to formulary with prescribing restrictions to pulmonary hypertension physicians  
  • Treprostin (Orenitram) tablets were ADDED to formulary with prescribing restrictions to pulmonary hypertension physicians  
  • Tadalafil (Adcirca tablets were ADDED to formulary with prescribing restrictions to pulmonary hypertension physicians  
  • Macitentan (Opsumit) tablets were ADDED to formulary with prescribing restrictions to pulmonary hypertension physicians  
  • Revisions to the Controlled Substance Administration Policy were APPROVED
  • Revisions to the Home Medication Policy were APPROVED